Skip to content

EBIT at other companies

Pfizer logo
PfizerPFE
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Exelixis logo
ExelixisEXEL
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Incyte logo
IncyteINCY
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Calculated from Nuvalent, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s EBIT?
Nuvalent, Inc. (NUVL) reported EBIT of -$119.41M in Q1 2026.
How has Nuvalent, Inc.'s EBIT changed year-over-year?
Nuvalent, Inc.'s EBIT decreased by 25.9% year-over-year, from -$94.81M to -$119.41M.
What is the long-term trend for Nuvalent, Inc.'s EBIT?
Over 4 years (2021 to 2025), Nuvalent, Inc.'s EBIT has grown at a 73.4% compound annual growth rate (CAGR), from -$45.82M to -$414.31M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.